Could investing in the pharmaceutical giant pay off over the next five years? I think so, and here is why. AbbVie has a ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Lynk Pharmaceuticals’ next generation JAK inhibitor, zemprocitinib, has met its primary and secondary trial endpoints during a Phase III study in rheumatoid arthritis. Image credit: one photo via ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost management strategies.

AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies ...

Rheumatoid arthritis begins years before pain ever appears, and scientists have now mapped the hidden immune battle that unfolds long before symptoms. By studying people with RA-linked antibodies over ...

The MarketWatch News Department was not involved in the creation of this content. Exton, PA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The 2025 Market Dynamix(TM): Psoriatic ...

AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...